C18-Ceramide in Head & Neck Cancer Growth and Therapy
C18-Ceramide in Head & Neck Cancer Growth and Therapy
批准号:
8687640
负责人:
Besim Ogretmen
金额:
$34.68万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-04-01 至 2015-12-31
关键词:
ApoptosisAutophagocytosisAutophagosomeBindingBiochemicalBiologicalCatabolic ProcessCell DeathCell SurvivalCeramidesComplexDataDevelopmentDigestionDiseaseDown-RegulationFatty AcidsFunctional disorderGenerationsGrowthHead and Neck CancerHead and Neck Squamous Cell CarcinomaHead and neck structureHomologous GeneHumanLeadLengthLightLinkMalignant Epithelial CellMammalsMediatingMembraneMetabolicMetabolismMicrotubule-Associated ProteinsMitochondriaPathogenesisPathway interactionsPatientsPharmaceutical PreparationsProteinsPublishingRegulationReportingRoleSignal TransductionSphingolipidsStarvationStreamStressTestingTherapeuticTimeTissuesTumor SuppressionUbiquitinVesicleanalogbasecancer cellclinically relevantdesigndihydroceramidedihydroceramide desaturasein vivomitochondrial dysfunctionnovelnovel strategiesnovel therapeuticspreventreconstitutionresearch studytreatment strategytumortumor growthtumor xenograft
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal is designed to test the overall hypothesis that reconstitution of C18-ceramide generation mediates lethal autophagy, subsequently leading to mitochondrial dysfunction, and suppression of HNSCC tumor growth. As a corollary, the hypothesis that treatment of HNSCCs with C18-ceramide analogues, such as C18-pyridinium-ceramide (C18-Pyr-Cer), which enhance LC3-lipidation and mitochondrial targeting, induces autophagy-mediated tumor suppression will also be tested. To test these novel hypotheses, three Specific Aims are proposed: Specific Aim 1. Determine the roles of CerS1-generated C18-(dihydro)ceramide in the regulation of HNSCC growth inhibition via induction of autophagy. Specific Aim 2. Define the down-stream mechanisms by which CerS1/C18-ceramide signaling induces lethal autophagy. Specific Aim 3. Define the roles of C18-ceramide and LC3-II in selective mitochondrial targeting of autophagosomes to enhance lethal autophagy and tumor suppression. Collectively, studies proposed in this application will help define novel mechanisms involved selectively in the regulation of lethal autophagy by C18-ceramide signaling, which subsequently leads to suppression of HNSCC tumor growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting AML Mitochondria by Ceramide
-
批准号:10546239
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2022
-
负责人:Besim Ogretmen
-
依托单位:
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
-
批准号:10253130
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2020
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
-
批准号:9930853
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2019
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10411382
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of PD-L1 signaling to control metastasis and resistance to immunotherapy in TNBC
-
批准号:10801345
-
项目类别:
-
资助金额:$37.11万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9977980
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10222592
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:10460230
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
-
批准号:9441547
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2018
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9072008
-
项目类别:
-
资助金额:$181.11万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Project 2: Regulation of Tumor Metastasis by Systemic S1P and Complement Signaling
-
批准号:9072014
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
-
批准号:9980696
-
项目类别:
-
资助金额:$174.77万
-
财政年份:2016
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:8585322
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9269533
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
Mechanisms of sphingolipid analogue drug FTY720-mediated NSCLC tumor suppression
-
批准号:9076632
-
项目类别:
-
资助金额:$31.02万
-
财政年份:2013
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8714006
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8514026
-
项目类别:
-
资助金额:$105.65万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:8305278
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
COBRE in Lipidomics and Pathobiology
-
批准号:9098741
-
项目类别:
-
资助金额:$109.48万
-
财政年份:2012
-
负责人:Besim Ogretmen
-
依托单位:
Lipidomics Shared Resource
-
批准号:10377471
-
项目类别:
-
资助金额:$6.18万
-
财政年份:2009
-
负责人:Besim Ogretmen
-
依托单位: